Safety of Intravenous Diltiazem in Reduced Ejection Fraction Heart Failure with Rapid Atrial Fibrillation

Background and Objective Diltiazem is a nondihydropyridine calcium channel blocker that is used to control rapid ventricular response in patients who have atrial fibrillation or flutter. Diltiazem has a negative inotropic effect and may cause hemodynamic decompensation in patients with reduced eject...

Full description

Saved in:
Bibliographic Details
Published in:Clinical drug investigation 2018-06, Vol.38 (6), p.503-508
Main Author: Jandali, Mohamad Badr
Format: Article
Language:English
Subjects:
Cardiac arrhythmia
Cardiomyopathy
Cardiovascular disease
Coronary vessels
Ejection fraction
Electrocardiography
Epidemiology
Heart attacks
Heart failure
Heart rate
Intensive care
Internal Medicine
Kidneys
Medicine
Medicine & Public Health
Mortality
Original Research Article
Pharmacology/Toxicology
Pharmacotherapy
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Objective Diltiazem is a nondihydropyridine calcium channel blocker that is used to control rapid ventricular response in patients who have atrial fibrillation or flutter. Diltiazem has a negative inotropic effect and may cause hemodynamic decompensation in patients with reduced ejection fraction. This study evaluated outcomes in patients who had low ejection fraction and were treated with diltiazem. Methods This was a retrospective chart review in 635 patients who were hospitalized because of rapid atrial fibrillation and who were treated with intravenous diltiazem. Outcomes were evaluated for patients in two groups based on ejection fraction (EF): normal (EF ≥ 50%) and low EF (EF 
ISSN:1173-2563
1179-1918
DOI:10.1007/s40261-018-0631-7